自 20 世纪 70 年代以来，利巴韦林一直被用作抗病毒药物来治疗多种病毒感染。过去几十年来，人们对利巴韦林的药理学进行了研究，并探索了其在新适应症中使用的可能性。根据多项研究结果，利巴韦林在治疗各种起源的恶性肿瘤方面的功效已得到证实。此外，由于使用手术方法治疗脑肿瘤的复杂性，将利巴韦林靶向递送至大脑成为现有治疗方法的有希望的替代方案。活性药物成分 (API) 靶向脑肿瘤是通过鼻到脑机制进行鼻内药物输送来实现的。此外，利用这种输送机制，可以绕过血脑屏障（BBB）到达大脑，从而避免首先通过肝脏的影响。尽管该方法具有显着的优点，但其应用存在限制因素——粘膜纤毛清除，其目的是清除鼻粘膜表面的异物。在原位，系统能够降低 API 干扰因素的强度，并在鼻内给药期间实现最大的生物利用度。版权所有 © Bentham Science Publishers；如有任何疑问，请发送电子邮件至 epub@benthamscience.net。

Ribavirin has been used as an antiviral agent to treat a variety of viral infections since the 1970s. Over the past few decades, studies have been conducted on the pharmacology of ribavirin, and the possibility of its use in new indications has been explored. According to the results of a number of studies, ribavirin efficacy in the therapy of malignant neoplasms of various genesis has been proven. Furthermore, due to the complexity of brain tumor therapy using surgical methods, targeted delivery of ribavirin to the brain becomes a promising alternative to existing treatment methods. Targeting of active pharmaceutical ingredient (API) to the brain tumor is achieved by intranasal drug delivery via a Nose-to-Brain mechanism. In addition, using this delivery mechanism, it is possible to reach the brain while bypassing the blood-brain barrier (BBB), thus avoiding the effects of the first passage through the liver. Despite the significant advantages of the method, there are limiting factors to its application - mucociliary clearance, which aims to remove foreign bodies from the surface of the nasal mucosa. In situ, systems are able to reduce the intensity of interfering factors on API and allow the achievement of maximum bioavailability during intranasal administration.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.